Published in Blood on December 13, 2013
Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov (2014) 3.54
Functions of BET proteins in erythroid gene expression. Blood (2015) 1.50
BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget (2015) 1.12
Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Ther Adv Hematol (2015) 1.06
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget (2015) 1.06
The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. Proc Natl Acad Sci U S A (2015) 1.05
The bromodomain: from epigenome reader to druggable target. Biochim Biophys Acta (2014) 1.02
Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes. Sci Transl Med (2014) 1.00
GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Sci Rep (2015) 0.97
Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Elife (2017) 0.95
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer (2015) 0.94
The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther (2016) 0.91
The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers. J Biol Chem (2014) 0.90
Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Br J Pharmacol (2014) 0.90
Targeting epigenetic regulations in cancer. Acta Biochim Biophys Sin (Shanghai) (2015) 0.88
Design and characterization of bivalent BET inhibitors. Nat Chem Biol (2016) 0.86
Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors. Cureus (2016) 0.85
Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress. Oncogene (2015) 0.82
Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model. Clin Cancer Res (2016) 0.79
Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. Bonekey Rep (2015) 0.79
Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer. PLoS Genet (2016) 0.79
Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma. J Cell Biochem (2016) 0.78
Preclinical activity of CPI-0610, a novel small molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. Leukemia (2016) 0.78
Targeting MYC as a therapeutic intervention for anaplastic thyroid cancer. J Clin Endocrinol Metab (2017) 0.77
Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia. Elife (2015) 0.77
Epigenetic modulators as therapeutic targets in prostate cancer. Clin Epigenetics (2016) 0.76
TgPRELID, a Mitochondrial Protein Linked to Multidrug Resistance in the Parasite Toxoplasma gondii. mSphere (2017) 0.76
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects. Onco Targets Ther (2016) 0.76
Bromodomain and Extra-terminal Proteins (BET) Inhibitors Suppress Chondrocyte Differentiation and Restrain Bone Growth. J Biol Chem (2016) 0.76
Erythropoiesis provides a BRD's eye view of BET protein function. Drug Discov Today Technol (2016) 0.76
Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL. Anticancer Drugs (2016) 0.75
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. Cancer Res (2017) 0.75
Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis. Oncotarget (2016) 0.75
Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development. Microbiol Mol Biol Rev (2017) 0.75
Epigenetics in cancer stem cells. Mol Cancer (2017) 0.75
Structural features and inhibitors of bromodomains. Drug Discov Today Technol (2016) 0.75
Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies. Cell Death Dis (2015) 0.75
A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers. Yale J Biol Med (2017) 0.75
I-BET151 inhibits expression of RANKL, OPG, MMP3 and MMP9 in ankylosing spondylitis in vivo and in vitro. Exp Ther Med (2017) 0.75
Suppression of inflammation by a synthetic histone mimic. Nature (2010) 8.80
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) 8.29
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat Immunol (2005) 5.83
Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol (2003) 5.36
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09
Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol (2010) 4.62
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol (2002) 3.91
Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis (2008) 3.84
Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem (2002) 3.81
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol (2003) 3.69
Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood (2002) 3.19
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol (2010) 3.18
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med (2005) 3.13
Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol Cell (2006) 3.08
LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol (2008) 2.85
Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother (2003) 2.65
Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood (2002) 2.59
Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol Cell (2013) 2.55
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A (2005) 2.49
Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem (2011) 2.45
Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol (2006) 2.38
IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J Immunol (2003) 2.28
Bone involvement in sickle cell disease. Br J Haematol (2005) 2.22
Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol (2006) 2.20
Left ventricular hypertrophy and diastolic dysfunction in children with sickle cell disease are related to asleep and waking oxygen desaturation. Blood (2010) 2.19
Suppression of the antiviral response by an influenza histone mimic. Nature (2012) 2.18
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J Med Chem (2013) 2.09
Lysine methylation of the NF-κB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-κB signaling. Nat Immunol (2010) 2.07
The role of mesenchymal stem cells in haemopoiesis. Blood Rev (2005) 1.98
Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. Nat Med (2006) 1.97
Rapid turnover of effector-memory CD4(+) T cells in healthy humans. J Exp Med (2004) 1.85
Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol (2007) 1.84
Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood (2002) 1.83
Management of Evans syndrome. Br J Haematol (2006) 1.76
Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci (2014) 1.69
Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood (2013) 1.68
Natural history of GATA1 mutations in Down syndrome. Blood (2003) 1.65
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood (2012) 1.64
Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. J Immunol (2006) 1.62
Measurement and modeling of human T cell kinetics. Eur J Immunol (2003) 1.61
Transfusion guidelines for neonates and older children. Br J Haematol (2004) 1.61
Fully functional memory CD8 T cells in the absence of CD4 T cells. J Immunol (2004) 1.59
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol (2006) 1.56
Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood (2008) 1.54
Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leuk Lymphoma (2013) 1.53
B-cell kinetics in humans: rapid turnover of peripheral blood memory cells. Blood (2005) 1.52
Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol (2003) 1.49
Qualitative differences between naïve and memory T cells. Immunology (2002) 1.48
Type I interferon as a stimulus for cross-priming. Cytokine Growth Factor Rev (2008) 1.48
Transperineal template-guided saturation biopsy using a modified technique: outcome of 270 cases requiring repeat prostate biopsy. BJU Int (2013) 1.46
Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proc Natl Acad Sci U S A (2012) 1.46
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood (2003) 1.44
Regulation of denitrification at the cellular level: a clue to the understanding of N2O emissions from soils. Philos Trans R Soc Lond B Biol Sci (2012) 1.43
Chemical composition of gases surgeons are exposed to during endoscopic urological resections. Urology (2009) 1.40
Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. Proc Natl Acad Sci U S A (2012) 1.39
Should centralized histopathological review in penile cancer be the global standard? BJU Int (2014) 1.39
Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis. Br J Haematol (2009) 1.38
Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic stability. Mol Cell Biol (2008) 1.37
In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection. Proc Natl Acad Sci U S A (2007) 1.36
Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. J Exp Med (2012) 1.36
In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology (2007) 1.35
Direct measurement of T cell subset kinetics in vivo in elderly men and women. J Immunol (2004) 1.34
In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci U S A (2008) 1.34
Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J Immunol (2005) 1.33
Role of arginine metabolism in immunity and immunopathology. Immunobiology (2007) 1.33
Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica (2010) 1.31
Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett (2008) 1.31
Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol (2009) 1.30
The oxidative stressor arsenite activates vascular endothelial growth factor mRNA transcription by an ATF4-dependent mechanism. J Biol Chem (2005) 1.30
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood (2012) 1.27
Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol (2005) 1.26
Local reactions to tick bites. Am J Dermatopathol (2008) 1.24
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg Med Chem Lett (2012) 1.24
Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther (2005) 1.23
Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer (2006) 1.21
Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol Cell Biol (2004) 1.21
Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J Neurochem (2007) 1.20
Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo. Hepatology (2011) 1.20
Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem Biol (2011) 1.20
A comparison of the functional modules identified from time course and static PPI network data. BMC Bioinformatics (2011) 1.20
Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics (2012) 1.19